A. N. Petrova¹, T. I. Ionova^2,3, A. V. Bykova¹, A. V. Zinkovskaya³, P. S. Krasikova^1,4, I. S. Nemchenko¹, T. P.Nikitina^2,3, N. M. Porfirieva³, E. Y. Chelysheva¹, A. O. Shukhov¹, N. N. Tsyba¹, A. G. Turkina¹

Quality of life in patients with chronic myeloid leukemia in deep molecular remission after stopping treatment with tyrosine kinase inhibitors: interim results

¹National Research Center for Hematology, Moscow
²Multinational Center for Quality of Life Research, Saint-Petersburg
³ N. I. Pirogov Clinic of high medical technologies, Saint-Petersburg State University, Saint-Petersburg
⁴Orenburg Region Clinical hospital, Orenburg

We aimed to study quality of life (QoL) in chronic myeloid leukemia in chronic phase (CML CP) patients with deep molecular response before stopping tyrosine kinase inhibitors (TKI) treatment and in different time points during treatment-free remission (TFR). It’s important for patients with chronic myeloid leukemia in chronic phase who achieved deep molecular response to provide the comprehensive assessment of their treatment outcomes, including quality of life along with clinical outcomes after stopping treatment with TKIs. We aimed to study QoL in CML CP patients with deep molecular response before stopping TKI treatment and in different time points during treatment-free remission. In the total, 99 CML CP patients were enrolled. All the patients received TKIs as 1st or 2nd line no less than 3 yrs (37–195 mos) and have stable MO4 (BCR-ABL <0,01) during ?2 yrs (24–129 mos). For QoL assessment all the patients filled out RAND SF-36 questionnaire before and 1, 3, 6 and 12 mos after stopping TKI treatment. Comparison group was consisted from healthy controls matched by age and gender to CML CP patients (n=97). QoL in CML CP patients with deep molecular response, who receive TKI treatment, slightly worth as compared to healthy controls; physical functioning in CML CP patients is significantly lower than in healthy controls. During 1 year of TFR the positive changes of role functioning, vitality and general health along with decreasing of some symptoms, related to TKI treatment, was revealed. The obtained results may contribute to developing recommendations to optimize monitoring of CML CP patients with deep molecular response during TFR.